Skip to main content
. 2019 May;10(3-4):80–96. doi: 10.18632/genesandcancer.192

Figure 5. DmrFABP5 reduced the level of phosphorylated PPARγ (p-PPARγ1 and p-PPARγ2) in prostate cancer cells.

Figure 5

A. Western blot analysis of p-PPARγ1 and p-PPARγ2 in benign and malignant prostate epithelial cells. B. Quantitative assessment of the levels of p-PPARγ1 and p-PPARγ2 in benign and malignant prostate cancer cells. C. Effect of 24 h treatments with PPARγ antagonist (GW9662), PPARγ agonist (Rosiglitazone), dmrFABP5, or a combination of dmrFABP5 and SB-FI-26 on levels of p-PPARγ1 and p-PPARγ2 in PC3-M cells. D. Quantitative assessment: Levels of both p-PPARγ1 and p-PPARγ2 in untreated PC3-M cells were set at 1; levels in the other treated cells were obtained by comparison with those in untreated PC3-M. E. Effect of 24 h treatments with wtrFABP5 or with a combination of wtrFABP5 and dmrFABP5 on levels of p-PPARγ1 and p-PPARγ2 in LNCaP cells. F. Quantitative assessment: Levels of p-PPARγ1 and p-PPARγ2 in control 22RV1 cells were set at 1; levels in the other treated cells were obtained by comparison with those in control. G. Effect of 24 h treatments with wtrFABP5, or with dmrFABP5 on levels of p-PPARγ1 and p-PPARγ2 in 22RV1 cells. H. Quantitative assessment: Levels of both p-PPARγ1 and p-PPARγ2 in the control were set at 1; levels in the other treated cells were obtained by comparison with those in controls. For each Western blot, anti-β-actin was also used to normalize for possible loading errors. Results (mean ± SE) were obtained from three separate experiments and the differences were assessed by 2-tailed unpaired Student's t test. *, p < 0.05; **, p < 0.001.